Compare BlackBerry Limited (BB) vs Pfizer Inc (PFE) Price & Performance

BlackBerry (BB) trades at $8.98, up 2.28% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats and a positive 2026 net income forecast of $60M signal a turnaround, though 2025 saw a net loss of $79M. The stock's valuation remains elevated with a P/E of 89.8 and P/S of 9.22. News highlights growth in QNX and secure communications, with the stock gaining 125% year-to-date as of August 2026, though it has pulled back 35% from its peak.

The outlook hinges on execution of growth in QNX and secure communications, with FY2027 guidance suggesting 11% revenue growth and 20% adjusted EBITDA margin expansion. Risks include premium valuation, cyclical industry exposure, and reliance on long-dated QNX royalties. Analyst consensus is cautious with 85.7% hold ratings, but a $10.50 price target implies potential upside if operational improvements materialize.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.